No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RPTX Repare Therapeutics
- 3.630
- -0.170-4.47%
Close Jun 18 16:00 ET
- 3.530
- -0.100-2.75%
Post 19:49 ET
154.08MMarket Cap-3300P/E (TTM)
3.860High3.530Low216.25KVolume3.860Open3.800Pre Close786.07KTurnover1.23%Turnover RatioLossP/E (Static)42.45MShares13.85052wk High0.66P/B64.02MFloat Cap2.98052wk Low--Dividend TTM17.64MShs Float46.440Historical High--Div YieldTTM8.68%Amplitude2.980Historical Low3.634Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Remix Therapeutics Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
Dr. Koehler brings over 20 years of oncology drug development leadership experience to Remix's Board of Directors WATERTOWN, Mass., June 18, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinica
Capital One Financial Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $21
Capital One Financial analyst Tim Chiang maintains $Repare Therapeutics(RPTX.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of
Express News | Foundation Medicine: Partnership to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Express News | Foundation Medicine: Co Announces Partnership With Repare Therapeutics
Foundation Medicine Announces Partnership With Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
Foundation Medicine, Inc., today announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in
Express News | Repare Therapeutics Inc- Repare Expects a Potential Data Readout in Camonsertib Monotherapy Nsclc Expansion in 2025
Comments
1
$Repare Therapeutics(RPTX.US$
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
1
$Repare Therapeutics(RPTX.US$
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Repare Therapeutics (Nasdaq: RPTX) announced that initial data from its Phase 1 MINOTAUR study will be presented at the European Society of Medical Oncology (ESMO) GI Congress 2024. The study evaluates the efficacy of lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors. This presentation is scheduled for June 27, 2024, at 3:35 PM CEST in Munich...
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Repare Therapeutics (Nasdaq: RPTX) announced that initial data from its Phase 1 MINOTAUR study will be presented at the European Society of Medical Oncology (ESMO) GI Congress 2024. The study evaluates the efficacy of lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors. This presentation is scheduled for June 27, 2024, at 3:35 PM CEST in Munich...
$Repare Therapeutics(RPTX.US$ Repare Therapeutics (NASDAQ:RPTX) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 136.14 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $52.40 million which beat the analyst consensus estimate of $38.40 million by 36.47 percent. This is a 822.93 percent increase over sales of $5.68 million the same period l...
2
2
$Repare Therapeutics(RPTX.US$
NEWS
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution o...
NEWS
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution o...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg